Abstract Background Filgotinib (FIL) is a once-daily, oral, Janus kinase 1 preferential inhibitor approved for the treatment of ulcerative colitis (UC). FIL 200 mg (FIL200) was effective in inducing and maintaining clinical remission vs placebo (PBO) well tolerated patients with UC randomized, phase 2b/3 SELECTION trial (NCT02914522).1 The efficacy safety continued FIL200 therapy are being asse...
